Switch from fingolimod to ozanimod for safety or intolerance reasons
Introduction: Ozanimod is a new-generation sphingosine-1-phosphate (S1P) modulator, approved for the treatment of multiple sclerosis (MS), offering higher selectivity for S1P receptor 1 and 5 (SPR1-5), minimizing potential safety concerns related to S1P3 receptor activation, compared to fingolimod....
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publishing
2025-07-01
|
| Seri Bilgileri: | Therapeutic Advances in Neurological Disorders |
| Online Erişim: | https://doi.org/10.1177/17562864251328191 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|